Cargando…

SUN-LB98 RAAS Triple-A Analysis for the Screening of Primary Aldosteronism

Primary aldosteronism (PA) is recognized as the most frequent cause of secondary hypertension, and its screening is expected to become a routine evaluation in most patients with hypertension. The interference of antihypertensive therapies with the aldosterone-to-renin ratio (ARR) during screening pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Burrello, Jacopo, Buffolo, Fabrizio, Domenig, Oliver, Tetti, Martina, Pecori, Alessio, Monticone, Silvia, Poglitsch, Marko, Mulatero, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208392/
http://dx.doi.org/10.1210/jendso/bvaa046.2299
_version_ 1783530834542723072
author Burrello, Jacopo
Buffolo, Fabrizio
Domenig, Oliver
Tetti, Martina
Pecori, Alessio
Monticone, Silvia
Poglitsch, Marko
Mulatero, Paolo
author_facet Burrello, Jacopo
Buffolo, Fabrizio
Domenig, Oliver
Tetti, Martina
Pecori, Alessio
Monticone, Silvia
Poglitsch, Marko
Mulatero, Paolo
author_sort Burrello, Jacopo
collection PubMed
description Primary aldosteronism (PA) is recognized as the most frequent cause of secondary hypertension, and its screening is expected to become a routine evaluation in most patients with hypertension. The interference of antihypertensive therapies with the aldosterone-to-renin ratio (ARR) during screening process is a major confounder. Renin-Angiotensin-Aldosterone System Triple-A (RAAS Triple-A) testing is a novel mass-spectrometry based assay for quantification of Angiotensin I (Ang I), Angiotenisn II (Ang II) and Aldosterone in a single sample of serum by RAAS equilibrium analysis. Obtained hormone levels are used to calculate markers for plasma-renin-activity (PRA-S, Ang I + Ang II), plasma angiotensin-converting-enzyme activity (ACE-S, Ang II-to-Ang I ratio) and adrenal function (AA2-Ratio, Aldosterone-to-Ang II ratio), with the latter being useful to screen for PA in hypertension. We performed a comparative evaluation of the diagnostic performance of the AA2-Ratio and 5 renin-based diagnostic ratios, differing in methods to determine aldosterone levels and renin activity in a cohort of 110 patients with hypertension (33 patients with confirmed primary aldosteronism and 77 with essential hypertension). All ratios showed comparable areas under the curves ranging between 0.924 and 0.970 without significant differences between each other. The evaluation of the ACE-S revealed persistent drug intake in some patients as cause for suppressed renin-based diagnostic ratios, while the AA2-Ratio remained unaffected. The Youden index optimal cutoff value for the AA2-Ratio was 6.6 ([pmol/L]/[pmol/L]) with a sensitivity of 90% and a specificity of 93%, proving non-inferiority compared with the ARR while pointing to the potential for an interference-free application in patients under ACE inhibitor therapy. This study shows for the first time the accuracy and reliability of RAAS Triple-A analysis for the screening of primary aldosteronism that can be applied in clinical routine.
format Online
Article
Text
id pubmed-7208392
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72083922020-05-13 SUN-LB98 RAAS Triple-A Analysis for the Screening of Primary Aldosteronism Burrello, Jacopo Buffolo, Fabrizio Domenig, Oliver Tetti, Martina Pecori, Alessio Monticone, Silvia Poglitsch, Marko Mulatero, Paolo J Endocr Soc Cardiovascular Endocrinology Primary aldosteronism (PA) is recognized as the most frequent cause of secondary hypertension, and its screening is expected to become a routine evaluation in most patients with hypertension. The interference of antihypertensive therapies with the aldosterone-to-renin ratio (ARR) during screening process is a major confounder. Renin-Angiotensin-Aldosterone System Triple-A (RAAS Triple-A) testing is a novel mass-spectrometry based assay for quantification of Angiotensin I (Ang I), Angiotenisn II (Ang II) and Aldosterone in a single sample of serum by RAAS equilibrium analysis. Obtained hormone levels are used to calculate markers for plasma-renin-activity (PRA-S, Ang I + Ang II), plasma angiotensin-converting-enzyme activity (ACE-S, Ang II-to-Ang I ratio) and adrenal function (AA2-Ratio, Aldosterone-to-Ang II ratio), with the latter being useful to screen for PA in hypertension. We performed a comparative evaluation of the diagnostic performance of the AA2-Ratio and 5 renin-based diagnostic ratios, differing in methods to determine aldosterone levels and renin activity in a cohort of 110 patients with hypertension (33 patients with confirmed primary aldosteronism and 77 with essential hypertension). All ratios showed comparable areas under the curves ranging between 0.924 and 0.970 without significant differences between each other. The evaluation of the ACE-S revealed persistent drug intake in some patients as cause for suppressed renin-based diagnostic ratios, while the AA2-Ratio remained unaffected. The Youden index optimal cutoff value for the AA2-Ratio was 6.6 ([pmol/L]/[pmol/L]) with a sensitivity of 90% and a specificity of 93%, proving non-inferiority compared with the ARR while pointing to the potential for an interference-free application in patients under ACE inhibitor therapy. This study shows for the first time the accuracy and reliability of RAAS Triple-A analysis for the screening of primary aldosteronism that can be applied in clinical routine. Oxford University Press 2020-05-08 /pmc/articles/PMC7208392/ http://dx.doi.org/10.1210/jendso/bvaa046.2299 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Cardiovascular Endocrinology
Burrello, Jacopo
Buffolo, Fabrizio
Domenig, Oliver
Tetti, Martina
Pecori, Alessio
Monticone, Silvia
Poglitsch, Marko
Mulatero, Paolo
SUN-LB98 RAAS Triple-A Analysis for the Screening of Primary Aldosteronism
title SUN-LB98 RAAS Triple-A Analysis for the Screening of Primary Aldosteronism
title_full SUN-LB98 RAAS Triple-A Analysis for the Screening of Primary Aldosteronism
title_fullStr SUN-LB98 RAAS Triple-A Analysis for the Screening of Primary Aldosteronism
title_full_unstemmed SUN-LB98 RAAS Triple-A Analysis for the Screening of Primary Aldosteronism
title_short SUN-LB98 RAAS Triple-A Analysis for the Screening of Primary Aldosteronism
title_sort sun-lb98 raas triple-a analysis for the screening of primary aldosteronism
topic Cardiovascular Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208392/
http://dx.doi.org/10.1210/jendso/bvaa046.2299
work_keys_str_mv AT burrellojacopo sunlb98raastripleaanalysisforthescreeningofprimaryaldosteronism
AT buffolofabrizio sunlb98raastripleaanalysisforthescreeningofprimaryaldosteronism
AT domenigoliver sunlb98raastripleaanalysisforthescreeningofprimaryaldosteronism
AT tettimartina sunlb98raastripleaanalysisforthescreeningofprimaryaldosteronism
AT pecorialessio sunlb98raastripleaanalysisforthescreeningofprimaryaldosteronism
AT monticonesilvia sunlb98raastripleaanalysisforthescreeningofprimaryaldosteronism
AT poglitschmarko sunlb98raastripleaanalysisforthescreeningofprimaryaldosteronism
AT mulateropaolo sunlb98raastripleaanalysisforthescreeningofprimaryaldosteronism